(Q34267233)

1 August 2017

1 reference

title

Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis (English)

1 reference

1 August 2017

0 references

venous thromboembolism

1 reference

1 reference

Therese M Chapman

1

1 reference

1 August 2017

Karen L Goa

series ordinal

2

1 reference

1 August 2017

publication date

1 January 2003

1 reference

1 August 2017

1 reference

1 August 2017

volume

63

1 reference

1 August 2017

issue

21

1 reference

1 August 2017

page(s)

2357-2377

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363210-00009

1 August 2017

exact match

0 references

cites work

The epidemiology of venous thromboembolism.

1 reference

12 December 2020

Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery

1 reference

12 December 2020

Heparins and venous thromboembolism: current practice and future directions

1 reference

12 December 2020

Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO-11).

1 reference

12 December 2020

Risk factors for venous thromboembolism

1 reference

12 December 2020

The treatment of venous thromboembolic disorders: new challenges and opportunities

1 reference

12 December 2020

Low-molecular-weight heparins

1 reference

12 December 2020

A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group

1 reference

12 December 2020

Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial

1 reference

12 December 2020

Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.

1 reference

12 December 2020

[Prophylactic antithrombotic therapy after orthopedic surgery with bemiparin, a second-generation low molecular weight heparin]

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

12 December 2020

Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Low molecular weight heparins--a safer option than unfractionated heparin?

1 reference

12 December 2020

High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death

1 reference

12 December 2020

Heparin and low molecular weight heparin: background and pharmacology

1 reference

12 December 2020

Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium

1 reference

12 December 2020

Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH (RO-11) in healthy subjects

1 reference

12 December 2020

Antithrombotic therapy for venous thromboembolic disease

1 reference

12 December 2020

In-vitro and ex-vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin

1 reference

12 December 2020

Comparative study of the pharmacokinetic profiles of two LMWHs—bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)—administered subcutaneously to healthy male volunteers

1 reference

12 December 2020

Risk factors for venous thromboembolism in general surgical patients.

1 reference

12 December 2020

FDA public health advisory.

1 reference

12 December 2020

High and low molecular weight heparins do not modify red blood cell aggregability in vitro

1 reference

12 December 2020

High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity--implications for cancer related thromboembolism and heparin therapy

1 reference

12 December 2020

Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis.

1 reference

12 December 2020

Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)--a three way cross-over study in healthy volunteers

1 reference

12 December 2020

Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses.

1 reference

12 December 2020

Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure

1 reference

12 December 2020

Treatment options for deep venous thrombosis

1 reference

12 December 2020

Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers--a dose-finding study within the therapeutical range

1 reference

12 December 2020

European practice guidelines: thromboembolism prophylaxis and regional anesthesia.

1 reference

12 December 2020

10.2165/00003495-200363210-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1030978338

0 references

Fatcat ID

release_a4avxlowwndyvatcevclibrlmi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a4avxlowwndyvatcevclibrlmi

24 November 2022

mapped directly with Wikidata item

1 reference